The global advanced therapy medicinal products (ATMP) CDMO market is on an impressive growth trajectory. Valued at USD 6.73 billion in 2024, it is projected to soar to USD 37.27 billion by 2034, growing at a CAGR of 18.82% from 2025 to 2034. This surge is fueled by an increasing number of rare diseases, infectious disease outbreaks, and a robust pipeline of ATMPs in clinical trials. Advancements in gene editing technologies like CRISPR, rising pharmaceutical R&D investments, and digital innovations such as AI-driven analytics are also accelerating market growth.
This article highlights the key companies shaping the ATMP CDMO landscape, alongside market trends and future prospects.
Market Overview
-
2024 Market Size: USD 6.73 billion
-
2034 Projected Size: USD 37.27 billion
-
CAGR (2025–2034): 18.82%
-
Top Region (2024): North America (45–50% share)
-
Fastest Growing Region: Asia Pacific (2025–2034)
-
Leading Segment (2024): Cell therapy products (35–38% revenue share)
-
Fastest Growing Segment: Gene therapy products
Top Advanced Therapy Medicinal Products CDMO Companies
1. AGC Biologics
About: A global leader in contract development and manufacturing, AGC Biologics specializes in cell and gene therapy, with a strong presence in biologics manufacturing.
Products: Viral vectors, cell therapies, plasmid DNA production.
Market Cap: Approx. USD 3.2 billion.
2. Aldevron (a Danaher Company)
About: Known for its high-quality plasmid DNA, RNA, and proteins, Aldevron serves biopharma and research markets globally.
Products: Custom plasmid DNA, mRNA, proteins for cell and gene therapies.
Market Cap: Parent Danaher’s market cap exceeds USD 190 billion.
3. Andelyn Biosciences
About: A leading CDMO focusing on viral vector production, Andelyn supports clinical and commercial development for ATMPs.
Products: Adeno-associated virus (AAV), lentivirus production services.
Market Cap: Privately held; estimated annual revenue USD 150M+.
4. BlueReg (a PharmaLex Company)
About: Offers regulatory consulting and development support for advanced therapies.
Products: Regulatory affairs, quality assurance, market authorization services.
Market Cap: Part of PharmaLex Group with estimated value USD 1.1 billion.
5. Brammer Bio (Thermo Fisher Scientific)
About: Specializes in viral vector manufacturing for gene therapies, acquired by Thermo Fisher in 2019.
Products: Clinical and commercial viral vector manufacturing.
Market Cap: Thermo Fisher’s market cap is over USD 220 billion.
6. Catalent Cell & Gene Therapy
About: Provides integrated services for gene therapy development from discovery to commercial launch.
Products: Plasmid DNA, viral vector manufacturing, cell therapy solutions.
Market Cap: Approx. USD 10.5 billion.
7. Center for Breakthrough Medicines
About: A full-service CDMO dedicated to accelerating cell and gene therapy programs.
Products: Viral vectors, cell processing, plasmid DNA manufacturing.
Market Cap: Privately held; projected valuation USD 500M+.
8. Charles River Laboratories
About: A trusted partner for biopharma companies, offering preclinical, clinical, and CDMO services.
Products: Plasmids, viral vectors, biologics testing solutions.
Market Cap: Approx. USD 12.8 billion.
9. Cytiva (Danaher)
About: A prominent player in bioprocessing technologies and solutions for ATMP manufacturing.
Products: Bioprocess equipment, viral vectors, custom manufacturing.
Market Cap: Included under Danaher’s USD 190 billion valuation.
10. Eurofins CDMO
About: Provides end-to-end services for biologics and ATMPs from development to commercialization.
Products: Cell & gene therapy services, bioanalytics, process development.
Market Cap: Approx. USD 13.4 billion.
11. Fujifilm Diosynth Biotechnologies
About: Offers contract development and manufacturing services for biologics and advanced therapies.
Products: Gene therapies, cell therapies, process development.
Market Cap: Parent Fujifilm’s market cap is approx. USD 50 billion.
12. Lonza
About: One of the largest CDMOs globally, Lonza is a key partner in ATMP manufacturing.
Products: Viral vectors, cell therapies, bioprocessing solutions.
Market Cap: Approx. USD 40 billion.
13. Minaris Regenerative Medicine
About: Focused on cell and gene therapies, Minaris offers global manufacturing solutions.
Products: Autologous and allogeneic cell therapy manufacturing.
Market Cap: Privately held; annual revenue estimated USD 250M+.
14. Novasep
About: Specializes in purification and production solutions for ATMPs.
Products: Viral vectors, bio-manufacturing services.
Market Cap: Privately owned; estimated value USD 800M+.
15. Oxford Biomedica
About: A leading gene and cell therapy company providing CDMO services worldwide.
Products: Lentiviral vectors, cell and gene therapy process development.
Market Cap: Approx. USD 600 million.
16. Porton Advanced
About: A China-based CDMO specializing in cell and gene therapy solutions.
Products: Viral vectors, cell processing services, regulatory support.
Market Cap: Parent company Porton Pharma Solutions’ market cap is USD 2.3 billion.
17. RoslinCT
About: A pioneer in cell therapy manufacturing, supporting development from clinical to commercial scale.
Products: Cell therapy manufacturing, process development.
Market Cap: Privately held; revenue around USD 50M+.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
FAQs About Advanced Therapy Medicinal Products CDMO Market
Q1: What are Advanced Therapy Medicinal Products (ATMPs)?
ATMPs include gene therapy, cell therapy, and tissue-engineered products designed to treat rare and complex diseases.
Q2: Why is the ATMP CDMO market growing so rapidly?
The rise in rare diseases, advanced gene-editing tools like CRISPR, and high investments in biopharma R&D are major growth drivers.
Q3: Which region dominates the ATMP CDMO market?
North America leads with nearly 50% market share, while Asia Pacific is the fastest-growing region.
Q4: Who are the top players in the ATMP CDMO industry?
Companies like Lonza, Catalent, Thermo Fisher, Fujifilm Diosynth Biotechnologies, and AGC Biologics are key leaders.
Q5: What is the projected CAGR for the ATMP CDMO market?
The market is expected to grow at a CAGR of 18.82% between 2025 and 2034.
Source : https://www.towardshealthcare.com/insights/advanced-therapy-medicinal-products-cdmo-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5868
About the Author
